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Introduction: According to current GOLD strategy, patients with COPD classified as groups A
and B may be treated with inhaled bronchodilators, either long-acting b2-agonist (LABA) or
long-acting muscarinic antagonist (LAMA). However, there is little guidance on which class
of agent is preferred and a lack of prospective data to differentiate the two.
Methods: In this study, we performed post-hoc analyses of pooled data from two prospective,
controlled clinical trials comparing the LABA indacaterol and LAMA tiotropium in 1422 patients
with moderate airflow limitation and no history of exacerbations in the previous year. This pop-
ulation fits the definitions of GOLD A and B groups and could be further stratified by symptom
severity using Baseline Dyspnea Index (i.e. modeling GOLD A or B) and inhaled corticosteroid
(ICS) use at baseline. Outcomes measured after 12 weeks of treatment were lung function
(forced expiratory volume in 1 s; FEV1), health status (St George’s Respiratory Questionnaire;
SGRQ), symptoms (Transition Dyspnea Index; TDI) and rescue medication use.
Results: In ‘GOLD A’ patients not receiving ICS, differences favored indacaterol versusmail.com (D.A. Mahler), h.a.m.kerstjens@umcg.nl (H.A.M. Kerstjens), james_donohue@med.unc.edu
ni-mainz.de (R. Buhl), davejlawrence@hotmail.com (D. Lawrence), pablo.altman@novartis.com (P.
5.05.012
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
nd/4.0/).
1032 D.A. Mahler et al.tiotropium (trough FEV1 0.05 L; rescue medication use 0.41 puffs/day; TDI total score 0.94
points; SGRQ total score 3.13 units, all p < 0.01). In ‘GOLD B, no ICS’ patients, compared with
tiotropium, indacaterol treatment increased trough FEV1 (0.055 L, p < 0.05) and permitted a
larger reduction in rescue medication use (0.81 puffs/day, pZ 0.004). In all patients, and in
patients not using ICS, differences favored indacaterol for all variables.
Conclusions: Our findings suggest that patients in GOLD groups A and B may experience greater
benefits with indacaterol than with tiotropium.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients with mild or moderate airflow limitation (forced
expiratory volume in 1 s [FEV1] 50% predicted), with fewer
than two exacerbations in the past year (not requiring
hospitalization), are classified as Global initiative for
chronic Obstructive Lung Disease (GOLD) groups A (fewer
symptoms) or B (more symptoms) [1]. The current recom-
mended drug treatment for such patients is bronchodila-
tors, ranging from short-acting agents given as needed to
long-acting agents given alone or in combination, the in-
tensity of treatment depending on the patient’s level of
symptoms [1]. There is a paucity of prospective studies
evaluating different bronchodilator treatments in these
groups; the available data are usually sub-analyses of larger
studies or pooled data [2e4].
We were interested to explore the comparative efficacy
and safety of the long-acting muscarinic antagonist (LAMA)
tiotropium and the long-acting b2-agonist (LABA) indaca-
terol, by means of a post-hoc analysis using data from two
randomized controlled trials that compared these agents in
patients with moderate-to-severe chronic obstructive pul-
monary disease (COPD) [5,6]. While entry criteria for those
trials were set before the new COPD GOLD assessment
scheme was published in 2011, it was possible to identify a
subgroup of patients who were within the GOLD groups A and
B, by virtue of FEV1 50% predicted (mild or moderate
airflow limitation) and a history of no exacerbations in the
previous year. This subgroup could be differentiated ac-
cording to baseline symptom severity to provide a close
match with the separate groups A (fewer symptoms) and B
(more symptoms). Although in the GOLD scheme inhaled
corticosteroids (ICS) should not be administered to patients
in GOLD groups A and B [1],many of these patients do receive
ICS in practice, which led us to analyze patients receiving ICS
separately. Our objective was to evaluate the comparative
efficacy and safety of indacaterol and tiotropium in patient
groups that closely modeled GOLD groups A and B.
2. Methods
2.1. Study design
Data were pooled from two randomized, parallel-group
trials. One trial compared indacaterol 150 mg, indacaterol
300 mg and placebo, double blinded, with open-label tio-
tropium 18 mg, all taken once daily for 6 months (INHANCE;
NCT00463567) [5]. The second, fully blinded trial(INTENSITY; NCT00900731) compared treatment with inda-
caterol 150 mg or tiotropium 18 mg, both taken once daily
for 12 weeks [6]. The latter trial did not include a placebo
treatment arm, and the placebo data from the other trial
were not included in the present analysis. Data for the
indacaterol 300 mg treatment group (in the INHANCE trial
only) were not included in the present analysis since 150 mg
is the starting dose, which is therefore relevant to the
subgroups evaluated here.
2.2. Patients
The entry criteria for the two source trials were almost
identical and have been fully described previously [5,6].
Briefly, the trials enrolled patients aged 40 years with
moderate-to-severe COPD (FEV1 <80% and 30% predicted;
FEV1/forced vital capacity 0.7), with a smoking history of
10 or 20 pack-years. Patients with a history of asthma or
a recent COPD exacerbation were not allowed into the
trial. A threshold level of symptoms was not required at
trial entry, but symptom severity was recorded at baseline,
together with information on whether patients had an
exacerbation in the previous year (the number of exacer-
bations was not captured). Patients receiving ICS continued
this treatment at an unchanged and stable dose during the
trial. Use of salbutamol as rescue medication was allowed
as needed, and recorded during the trial. Patients gave
their written informed consent, and the trials were
approved by the ethics committees or review boards at the
investigating centers.
For the present analysis, we identified a subgroup of
patients who were defined at the time of trial entry as
having mild or moderate COPD (now classified as airflow
limitation of GOLD grade 1 or 2; post-bronchodilator FEV1
50% predicted) and no exacerbations in the year prior to
trial entry. This subgroup could be further divided accord-
ing to ICS use at baseline (yes or no) and the severity of
dyspnea, according to the Baseline Dyspnea Index (BDI)
score (7 or <7). The modified Medical Research Council
(mMRC) scale, which measures breathlessness and is
included in the GOLD assessment, was measured in only one
of the two trials and was therefore not considered for the
present analysis. BDI cut-off values of 7 and <7 were
chosen because 7 was the median score both in the pooled
population and in the trial in which mMRC was recorded (in
that trial, 48% of patients had mMRC scores of 0 or 1 and
52% had mMRC scores of 2 or more). Additionally, 7 is the
mid-point of the 13-point BDI scale. We believe therefore
that the BDI provides a comparable split to mMRC.
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Spirometry was performed at clinic visits using standard
techniques. Trough FEV1 was the mean of measurements at
23 h 10 min and 23 h 45 min post dose. For both trials from
which the data were derived, trough FEV1 at 12 weeks was
the primary efficacy variable. A difference versus placebo
of 100 mL has been reported as the minimum clinically
important difference (MCID) [7].
Dyspnea was assessed by BDI at baseline and Transition
Dyspnea Index (TDI) total score at 12 weeks [8,9]. The TDI
score measures the change from baseline state (BDI), and
the MCID is 1 point [10]. Health status was assessed by St
George’s Respiratory Questionnaire (SGRQ) total score at 12
weeks. The MCID of the SGRQ total score is 4 units,
compared with either baseline or placebo [11,12]. The use
of salbutamol as rescue medication was recorded by pa-
tients in daily diaries and analyzed as the mean change
from baseline over 12 weeks. Reported adverse events
(AEs) during the entire study periods (6 months for INHANCE
and 12 weeks for INTENSITY) were summarized and
adjusted for length of exposure to treatment.
2.4. Statistical analysis
Trough FEV1 after 12 weeks of treatment was analyzed
using a mixed-effect model analysis of covariance with
treatment, smoking status, country, and study as fixed ef-
fects and baseline FEV1 and FEV1 reversibility as covariates.
Center nested within country was also included as a random
effect except where this resulted in non-convergence of
the model. In these cases (this applied to the responder
analysis for FEV1 for all subgroups apart from the ‘All pa-
tients’ group), center within country was not included. The
same model (with appropriate covariates) was used to
analyze mean TDI and SGRQ scores and rescue medication
use. For trough FEV1, TDI and SGRQ scores, missing values
were imputed by carrying forward the last observation as
long as it occurred at least 28 days after randomization.
Data are presented as least squares means with standard
errors or associated 95% confidence intervals for differ-
ences between treatments.
The proportions of patients who achieved the MCID
improvement in trough FEV1 (0.100 L), TDI or SGRQ
(changes of at least þ1 unit and 4 units, respectively)
were analyzed using logistic regression. The model included
the same covariates as for trough FEV1 with the inclusion of
the appropriate baseline value. The estimated adjusted
odds ratios (OR) were calculated along with the associated
95% confidence intervals.
No powering or sample size calculations were performed
for this post-hoc analysis, and no adjustment was made for
multiplicity.
3. Results
3.1. Defined subgroups
The patient subgroups were labeled as follows. The whole
group of ‘All patients’ (nZ 1422) comprised patients with
FEV1 50% predicted and no exacerbations in the previousyear. The ‘All patients’ subgroup was further divided ac-
cording to baseline ICS use as ‘All patients, no ICS’
(n Z 806) and ‘All patients, with ICS’ (n Z 616). BDI data
were available for 1393 patients, who were described as
‘GOLD A’ (having a BDI score of 7, i.e. fewer symptoms)
(nZ 822) or ‘GOLD B’ (having a BDI score of <7, i.e. more
symptoms) (nZ 571). Patients in the two latter groups not
receiving ICS at baseline were described, respectively, as
‘GOLD A, no ICS’ (n Z 505) and ‘GOLD B, no ICS’
(n Z 287).
3.2. Patient disposition and baseline characteristics
In the ‘All patients’ group, nearly all the patients
(n Z 1376, 97%) had moderate airflow limitation and 43%
were receiving ICS. The ‘All patients’ group represented
59% of the patients in the two source trials combined. Of
the 700 patients in the tiotropium group, 467 (67%) were
from INTENSITY and had received treatment in a blinded
fashion. Among the patients with BDI data, 41% had BDI
scores <7 points (more severe symptoms).
Table 1 shows the baseline characteristics of all patients
and the no-ICS subgroups. The two treatment groups
matched closely for each subgroup. Compared with ‘GOLD
A, no ICS’, the ‘GOLD B, no ICS’ patients tended to have a
longer duration of COPD (by w2 years), a longer smoking
history (by w3e4 years) and a slightly lower post-
bronchodilator FEV1 (by 70e110 mL). Their rescue use
was higher (w1.5 puffs/day) and, most notably, the SGRQ
score was w20 units worse.
Baseline data for the remaining subgroups are shown in
Supplementary Table S1. Compared with the ‘GOLD A’
subgroup, the ‘GOLD B’ subgroup had a longer duration of
COPD (1e2 years), higher frequency of ICS use, longer
smoking history, used more rescue medication (by about 1.5
puffs/day), and had a worse SGRQ score by about 20 units.
Similarly, the ‘All patients with ICS’ (compared with ‘All
patients, no ICS’) (Tables 1 and S1) had a longer duration of
COPD (w2 years), used more rescue medication (about 1
puff/day) and had a lower (worse) dyspnea score (w0.5
point). SGRQ scores were similar.
3.3. Efficacy
In the ‘All patients’ group, indacaterol was more efficacious
than tiotropium, with statistically significant differences
for trough FEV1 (30 mL), rescue use, TDI and SGRQ.
Indacaterol-treated patients were significantly and 36e50%
more likely to achieve the MCID in FEV1, TDI and SGRQ
(Table 2).
In the ‘All patients, no ICS’ subgroup, and in the ‘GOLD A,
no ICS’ subgroup, indacaterol had improved efficacy over
tiotropium, with significant differences in all variables apart
from the percentage of FEV1 responders (Tables 3 and 4).
In the smaller ‘GOLD B, no ICS’ subgroup, statistically
significantly greater improvements were observed in trough
FEV1 and rescue medication use with indacaterol compared
with tiotropium (Table 5).
The changes from baseline in trough FEV1 and SGRQ and
the TDI scores in each of the subgroups are depicted in
Fig. 1.
Table 1 Baseline characteristics of patients in the ‘All patients’ group and the no-ICS subgroups.
‘All patients’ ‘All patients, no ICS’ ‘GOLD A, no ICS’ ‘GOLD B, no ICS’
IND150 TIO IND150 TIO IND150 TIO IND150 TIO
N 722 700 407 399 256 249 143 144
Age, years 64 (8.9) 64 (8.6) 63 (8.9) 63 (8.8) 63 (8.5) 62 (8.5) 63 (9.5) 64 (9.2)
Male, % 64 63 63 63 64 64 63 61
Duration of COPD, years 6.5 (6.16) 6.8 (6.60) 5.4 (5.34) 6.0 (6.28) 4.5 (4.23) 5.2 (5.25) 6.8 (6.68) 7.0 (7.29)
Mild/moderate
airflow limitation, %
3/97 3/97 5/95 4/96 5/95 3/97 4/96 4/96
ICS use, % 44 43 0 0 0 0 0 0
Smoking history, years 44 (20.5) 44 (22.3) 44 (21.1) 44 (21.1) 43 (19.6) 43 (20.1) 46 (23.7) 47 (22.6)
FEV1 post-SABA
at screening, L
1.75
(0.432)
1.73
(0.433)
1.79
(0.446)
1.79
(0.452)
1.82
(0.439)
1.83
(0.454)
1.75
(0.463)
1.72
(0.438)
Rescue use, puffs/day 3.1 (3.57) 3.2 (3.19) 2.6 (3.20) 2.8 (3.13) 2.2 (2.51) 2.3 (3.04) 3.5 (3.93) 3.7 (3.05)
SGRQ total score, units 40 (18.0) 41 (17.8) 38 (17.8) 41 (17.3) 31 (14.9) 34 (14.4) 49 (16.4) 53 (15.1)
BDI total score, points 7.1 (2.26) 7.0 (2.18) 7.4 (2.34) 7.2 (2.08) 8.7 (1.50) 8.5 (1.36) 5.0 (1.44) 5.1 (1.19)
Data are mean (SD) unless otherwise stated. BDI, Baseline Dyspnea Index; COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 s; ICS, inhaled corticosteroids; IND150, indacaterol 150 mg; SABA, short-acting b2-agonist; SD, standard deviation;
SGRQ, St George’s Respiratory Questionnaire; TIO, tiotropium 18 mg.
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the Supplementary Tables S2eS6. For all comparisons,
indacaterol was either significantly better than or not
significantly different from tiotropium. In the ‘with ICS’
subgroups, the effects of indacaterol and tiotropium were
largely similar, although indacaterol was generally more
effective in improving health status (Tables S2, S5 and S6).
3.4. Safety
Table 6 shows the overall incidence of and the most
frequently occurring AEs and serious adverse events (SAEs).
Although there was a numerically larger rate of AEs with
indacaterol, the reverse was true for the rate of SAEs. Two
patients died: one was a sudden death at home (a 52-year-
old man receiving indacaterol in the INHANCE study) and
the other was a result of cardiac arrest (a 62-year-old man
receiving tiotropium in the INTENSITY study). Neither death
was suspected by the investigator of being related to theTable 2 Efficacy in the ‘All patients’ group after 12 weeks of t
Variable No. of patients
(IND150)
No. of patients
(TIO)
D
L
Trough FEV1, L 663 648 0
Patients with 0.10 L
improvement in FEV1
383/663 340/648 O
Change in rescue use,
puffs/day
680 654 
TDI total score, points 662 639 0
Patients with 1-point
improvement in TDI
413/662 339/639 O
SGRQ total score, units 664 647 
Patients with 4-unit
improvement in SGRQ
337/664 275/647 O
CI, confidence interval; IND150, indacaterol 150 mg; FEV1, forced expi
standard error; SGRQ, St George’s Respiratory Questionnaire; TDI, Trstudy drug. AE data were comparable between treatments
in the various subgroups (not shown).
4. Discussion
The major findings of these post-hoc pooled analyses were
that indacaterol provided greater improvements in trough
FEV1, dyspnea and health status compared with tiotropium
after 12 weeks in subgroups of patients with mild or mod-
erate COPD and no history of exacerbations, irrespective of
symptom severity. In the ‘All patients, no ICS’ subgroup,
indacaterol performed better than tiotropium for the out-
comes measured. In ‘GOLD A, no ICS’ patients, indacaterol
performed better than tiotropium for all outcomes, while in
‘GOLD B, no ICS’ patients the two treatments were gener-
ally similarly efficacious, although indacaterol treatment
permitted a larger increase in trough FEV1 and reduction in
rescue medication use.reatment.
ifference, IND150TIO,
SM or OR
SE 95% CI p-Value
.03 0.011 0.01, 0.05 0.002
R Z 1.36 1.06, 1.75 0.017
0.45 0.104 0.65, 0.24 <0.0001
.59 0.158 0.28, 0.90 0.0002
R Z 1.50 1.20, 1.89 0.0005
2.48 0.605 3.66, 1.29 <0.0001
R Z 1.49 1.18, 1.87 0.0008
ratory volume in 1 s; LSM, least squares mean; OR, odds ratio; SE,
ansition Dyspnea Index; TIO, tiotropium 18 mg.
Table 3 Efficacy in the ‘All patients, no ICS’ subgroup after 12 weeks of treatment.
Variable No. of patients
(IND150)
No. of patients
(TIO)
Difference, IND150TIO,
LSM or OR
SE 95% CI p-Value
Trough FEV1, L 375 367 0.05 0.015 0.02, 0.08 0.0008
Patients with 0.10 L
improvement in FEV1
207/375 187/367 OR Z 1.36 0.98, 1.88 0.068
Change in rescue use,
puffs/day
382 375 0.54 0.128 0.79, 0.29 <0.0001
TDI total score, points 375 359 0.77 0.204 0.37, 1.17 0.0002
Patients with 1-point
improvement in TDI
242/375 196/359 OR Z 1.66 1.21, 2.29 0.0018
SGRQ total score, units 373 363 2.08 0.833 3.71, 0.44 0.013
Patients with 4-unit
improvement in SGRQ
192/373 159/363 OR Z 1.47 1.08, 2.01 0.015
CI, confidence interval; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; IND150, indacaterol 150 mg; LSM, least
squares mean; OR, odds ratio; SE, standard error; SGRQ, St George’s Respiratory Questionnaire; TDI, Transition Dyspnea Index;
TIO, tiotropium 18 mg.
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tion and worse symptom scores in the ‘with ICS’ subgroups,
and a higher level of ICS use among patients with the worse
BDI scores. ICS treatment is not recommended for patients
in GOLD A and B groups [1]. When the present trials were
being performed, the GOLD recommendations were to
reserve ICS for patients with stage 3 or 4 (severe or very
severe) airflow limitation and repeated exacerbations [13].
In our population, it is conceivable that ICS were being
inappropriately prescribed for patients with more severe
symptoms rather than for patients at high risk of exacer-
bations [1], although it is also possible that ICS were being
used for patients with exacerbations, lowering the fre-
quency to below one a year. Inappropriate use of ICS in
patients with moderate COPD has been reported elsewhere
[14e16], despite the risk of side effects associated with this
form of treatment [17]. When patients were stratified on
the basis of symptoms, the resulting groups with more
symptoms were similar in terms of airflow limitation
compared with those with fewer symptoms, but there were
large differences in health status. While symptoms are oneTable 4 Efficacy in the ‘GOLD A, no ICS’ subgroup after 12 wee
Variable No. of patients
(IND150)
No. of patients
(TIO)
Trough FEV1, L 239 232
Patients with 0.10 L
improvement in FEV1
128/239 118/232
Change in rescue use,
puffs/day
243 235
TDI total score, points 241 231
Patients with 1-point
improvement in TDI
159/241 126/231
SGRQ total score, units 238 232
Patients with 4-unit
improvement in SGRQ
125/238 96/232
CI, confidence interval; FEV1, forced expiratory volume in 1 s; GOLD, G
corticosteroids; IND150, indacaterol 150 mg; LSM, least squares mean;
Questionnaire; TDI, Transition Dyspnea Index; TIO, tiotropium 18 mg.of the domains in SGRQ, the data illustrate the importance
of symptoms, specifically dyspnea, to the broader aspects
of a patient’s life. SGRQ scores in the present analysis
(‘Group A’, 33e34; ‘Group B’, 50e52 units) were similar to
those of group A and B patients in the ECLIPSE cohort (32
and 55 units, respectively). In that study, the risk of exac-
erbation and mortality in ‘Group B’ was similar to that in
‘Group C’ despite their moderate airflow limitation, indi-
cating that the importance of symptoms for risk and poor
outcomes should not be overlooked [18].
Current GOLD recommendations provide a multi-modal
patient assessment model including airflow limitation,
exacerbation history and symptom severity. The model al-
lows for the use of a simple measure of symptoms such as
the modified Medical Research Council (mMRC) scale, but
recommends a more comprehensive assessment of symp-
toms and their impact on health status using the COPD
Assessment Test (CAT) or COPD Control Questionnaire. The
SGRQ, commonly used to assess the effects of drug treat-
ment on health status in clinical trials, is regarded as too
complex for routine use [1]. The BDI/TDI requires someks of treatment.
Difference, IND150TIO,
LSM or OR
SE 95% CI p-Value
0.05 0.018 0.01, 0.08 0.008
OR Z 1.26 0.82, 1.92 0.287
0.41 0.132 0.67, 0.15 0.002
0.94 0.254 0.44, 1.44 0.0002
OR Z 1.93 1.27, 2.93 0.002
3.13 0.950 5.00, 1.26 0.001
OR Z 1.77 1.18, 2.66 0.006
lobal initiative for chronic Obstructive Lung Disease; ICS, inhaled
OR, odds ratio; SE, standard error; SGRQ, St George’s Respiratory
Table 5 Efficacy in the ‘GOLD B, no ICS’ subgroup after 12 weeks of treatment.
Variable No. of patients
(IND150)
No. of patients
(TIO)
Difference, IND150TIO,
LSM or OR
SE 95% CI p-Value
Trough FEV1, L 129 129 0.055 0.028 0.00, 0.110 0.049
Patients with 0.10 L
improvement in FEV1
76/129 67/129 OR Z 1.52 0.85, 2.73 0.154
Change in rescue use,
puffs/day
132 134 0.81 0.277 1.36, 0.27 0.004
TDI total score, points 134 128 0.65 0.372 0.09, 1.38 0.083
Patients with 1-point
improvement in TDI
83/134 70/128 OR Z 1.64 0.94, 2.86 0.082
SGRQ total score, units 129 125 0.79 1.674 4.09, 2.51 0.636
Patients with 4-unit
improvement in SGRQ
64/129 59/125 OR Z 1.19 0.67, 2.09 0.554
CI, confidence interval; FEV1, forced expiratory volume in 1 s; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled
corticosteroids; IND150, indacaterol 150 mg; LSM, least squares mean; OR, odds ratio; SE, standard error; SGRQ, St George’s Respiratory
Questionnaire; TDI, Transition Dyspnea Index; TIO, tiotropium 18 mg.
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and selecting a score, meaning that the measure is better
suited for use in clinical trials rather than everyday practice
[10]. A computerized version completed by the patient is
also available [19]. However, because mMRC was used only
in one of the source trials [5], BDI was chosen to define the
subgroups in the present analysis and provided a split of
similar proportions to those defined by mMRC (0e1 or 2). A
previous report using factor analysis showed that mMRC and
BDI were almost identical in their correlations with physio-
logic data and performed almost the same in assessing
dyspnea in COPD patients, with similar (normal) distribu-
tions [20]. Therefore, the BDI is considered a suitable sur-
rogate for defining the patients based on symptoms, given
that dyspnea is the major symptom of patients with COPD.
The patient groups in the present analysis are also
indirectly comparable to GOLD A and B in terms of baseline
SGRQ scores, which have been shown to correlate with CAT
scores, one of the GOLD-recommended assessments, with
CAT scores of <10 and 10 used to discriminate GOLD A and
B. In the ‘no-ICS, BDI 7’ patients in the present analysis
(‘GOLD A’), their mean baseline SGRQ scores of 31e34 units
would approximate to a CAT score of 12, while SGRQ scores
of 49e53 units in the ‘no-ICS, BDI <7’ patients (‘GOLD B’)
translate to a CAT score of about 20 [21]. Nevertheless, the
subgroup analysis does not fully model GOLD groups A and
B. Because the original trials only recorded whether an
exacerbation had occurred in the last year rather than the
number of events, the resulting patient subgroups (no ex-
acerbations in past year) are probably lower risk than the
GOLD groups A and B, which allow for an exacerbation
(provided not resulting in hospitalization) in the previous
year.
The present data set was pooled from two randomized,
prospective trials with closely similar designs and patient
inclusion criteria. Other prospective comparisons between
indacaterol and tiotropium conducted by the same sponsor
were not appropriate for inclusion in the present data set
owing to differences in study design and patient pop-
ulations. A third-party blinded crossover comparison in
patients with moderate-to-severe COPD had a treatmentduration of only 14 days [22] and reported a 40 mL advan-
tage in trough FEV1 for indacaterol 150 mg. A 52-week
comparison was conducted in patients with severe and
very severe COPD and at least one exacerbation in the
previous year (GOLD groups C þ D, although defined by
airflow limitation rather than exacerbation history) [2].
Three potential limitations to this analysis are
acknowledged. First, there is potential bias due to open-
label administration in one-third of the patients receiving
tiotropium, since patients’ subjective assessments may be
affected by previous experience with the drug. In the
blinded comparison, from which 66% of the present patients
were drawn, indacaterol and tiotropium were not signifi-
cantly different in their effect on trough FEV1 at 12 weeks,
but significant differences in favor of indacaterol were
observed for TDI (0.58 points, OR 1.49) and SGRQ (2.1
units, OR 1.43) as well as rescue medication use (0.54
puffs/day) [6]. These data were very similar to the differ-
ences in the whole subgroup of ‘All patients’ in the present
analysis (TDI, 0.59 points, OR 1.50; SGRQ 2.5 units, OR
1.49; rescue use 0.45 puffs/day; see Table 2). Further-
more, smaller differences between indacaterol and tio-
tropium in many subjective variables in the open-label
study [5] than in the fully blinded study [6] argue against a
major confounding effect of open-label tiotropium.
Second, the 12-week duration may not have been long
enough for treatment-associated improvements in patients’
health status to evolve fully [23]. However, 12 weeks is a
realistic timeframe in terms of any improvements that
might be expected to occur when treatments are initiated
in primary care, and would be more acceptable to both
patients and physicians than would changes that require a
longer period to become manifest. In analysis of data from
the 26-week INHANCE study, there was a significant 2.3
unit treatment difference (p  0.01) between indacaterol
150 mg and tiotropium 18 mg in SGRQ total score [5]. Addi-
tionally, a recent post-hoc analysis of indacaterol trials
compared the efficacy of indacaterol with placebo and
tiotropium in GOLD A and B patients over 6 months [24]. In
this analysis, although not significant, the difference in
SGRQ score was larger between indacaterol and placebo
Figure 1 Changes from baseline to week 12 in (a) trough
FEV1 (%) and (b) SGRQ total score, and (c) TDI total score. Data
are LSM  standard errors. Absolute values (LSM) for changes
from baseline in trough FEV1 with indacaterol and tiotropium
were, respectively, in the ‘All patients’ group: 0.152 and
0.119 L; ‘All patients, no ICS’: 0.151 and 0.102 L; ‘GOLD A, no
ICS’: 0.154 and 0.106 L; ‘GOLD B, no ICS’: 0.199 and 0.143 L.
FEV1, forced expiratory volume in 1 s; GOLD, Global initiative
for chronic Obstructive Lung Disease; ICS, inhaled corticoste-
roids; LSM, least squares mean; SGRQ, St George’s Respiratory
Questionnaire; TDI, Transition Dyspnea Index.
Table 6 AEs overall and most frequently occurring (inci-
dence in either treatment group 0.05 per patient-year for
AEs and 0.01 per patient-year for SAEs) adjusted for
exposure in the ‘All patients’ group.
Indacaterol
150 mg
Tiotropium
18 mg
Patients (n) 722 700
Patients with 1 AE 411 359
Total patient-years 249.9 202.5
Number of AEs
(AEs per patient-year)
1346 (5.39) 1036 (5.12)
COPD worsening 104 (0.42) 80 (0.40)
Headache 67 (0.27) 48 (0.24)
Nasopharyngitis 62 (0.25) 54 (0.27)
Cough 53 (0.21) 38 (0.19)
Upper respiratory
tract infection
36 (0.14) 21 (0.10)
Muscle spasms 35 (0.14) 4 (0.02)
Influenza 24 (0.10) 10 (0.05)
Sinusitis 23 (0.09) 10 (0.05)
Back pain 19 (0.08) 14 (0.07)
Arthralgia 18 (0.07) 5 (0.02)
Oropharyngeal pain 17 (0.07) 15 (0.07)
Dyspnea 16 (0.06) 17 (0.08)
Bronchitis 16 (0.06) 11 (0.05)
Lower respiratory
tract infection
16 (0.06) 10 (0.05)
Viral upper respiratory
tract infection
15 (0.06) 8 (0.04)
Hypertension 15 (0.06) 7 (0.03)
Nausea 15 (0.06) 6 (0.03)
Diarrhea 14 (0.06) 7 (0.03)
Urinary tract infection 13 (0.05) 15 (0.07)
Dry mouth 5 (0.02) 25 (0.12)
SAEs (per patient-year)
Patients with 1 SAE 33 36
Total patient-years 249.9 202.5
Number of SAEs
(AEs per patient-year)
49 (0.20) 56 (0.28)
COPD 7 (0.03) 5 (0.02)
Angina pectoris 3 (0.01) 0
Coronary artery disease 3 (0.01) 1 (0.01)
Atrial fibrillation 2 (0.01) 3 (0.02)
Pneumonia 2 (0.01) 2 (0.01)
Syncope 2 (0.01) 2 (0.01)
Arrhythmia 0 2 (0.01)
Coronary artery occlusion 0 2 (0.01)
Peripheral arterial
occlusive disease
0 2 (0.01)
AEs, adverse events; COPD, chronic obstructive pulmonary
disease; SAEs, serious adverse events.
Indacaterol vs tiotropium in COPD patients 1037compared with tiotropium and placebo in GOLD A and B
patients. Indacaterol 150 mg was the only treatment that
significantly improved SGRQ total score compared with
placebo in GOLD A patients [24].
Third, increasing levels of stratification resulted in small
numbers of patients and may have contributed to the lack
of statistically significant treatment differences in some of
the subgroups, especially in the ‘GOLD B, no ICS’ subgroup.
Nevertheless, overall, significant differences wereobserved and allow some conclusions to be drawn in terms
of appropriate treatment and the effects of long-acting
bronchodilators in these groups.
The results confirm the value of long-acting bronchodi-
lator treatment in patients with COPD in GOLD group A and
B patients. They also show that many such patients are
treated with ICS, contrary to the previous or currently
1038 D.A. Mahler et al.recommended GOLD treatment strategy, and suggest that
patients may have been given ICS on the basis of symptoms
alone rather than recommended predictors of risk (i.e.
airflow limitation and history of frequent exacerbations),
although it acknowledged that theoretically a very good
response to ICS may also have accounted for the lack of
exacerbations. Compared with tiotropium, indacaterol
improved lung function and provided a greater benefit in
terms of dyspnea and health status in the population of
patients with largely moderate airflow limitation and no
exacerbations in the previous year. Indacaterol was more
efficacious than tiotropium in the subgroup with fewer
symptoms, classed as GOLD A in the present analysis, with
significant improvements in lung function, less dyspnea and
rescue use, and better health status. Our findings suggest
that patients in GOLD groups A and B may experience
greater benefits with indacaterol than with tiotropium.Role of the funding source
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